Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech's challenge.

DNA vaccination has been widely explored to develop new, alternative and efficient vaccines for cancer immunotherapy. DNA vaccines offer several benefits such as specific targeting, use of multiple genes to enhance immunity and reduced risk compared to conventional vaccines. Rapid developments in molecular biology and immunoinformatics enable rational design approaches. These technologies allow construction of DNA vaccines encoding selected tumor antigens together with molecules to direct and amplify the desired effector pathways, as well as highly targeted vaccines aimed at specific epitopes. Reliable predictions of immunogenic T cell epitope peptides are crucial for rational vaccine design and represent a key problem in immunoinformatics. Computational approaches have been developed to facilitate the process of epitope detection and show potential applications to the immunotherapeutic treatment of cancer. In this review a number of different epitope prediction methods are briefly illustrated and effective use of these resources to support experimental studies is described. Epitope-driven vaccine design employs these bioinformatics algorithms to identify potential targets of vaccines against cancer. In this paper the selection of T cell epitopes to develop epitope-based vaccines, the need for CD4(+) T cell help for improved vaccines and the assessment of vaccine performance against tumor are reviewed. We focused on two applications, namely prediction of novel T cell epitopes and epitope enhancement by sequence modification, and combined rationale design with bioinformatics for creation of new synthetic mini-genes. This review describes the development of epitope-based DNA vaccines and their antitumor effects in preclinical research against B-cell lymphoma, corroborating the usefulness of this platform as a potential tool for cancer therapy. Achievements in the field of DNA vaccines allow to overcome hurdles to clinical translation. In a scenario where the vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach, these new technologies promise to discover and develop high-value vaccines, creating a new opportunity for future markets.

[1]  V. Giudicelli,et al.  IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. , 2003, Developmental and comparative immunology.

[2]  N. Fairweather,et al.  Immunization of mice with DNA encoding fragment C of tetanus toxin. , 1997, Vaccine.

[3]  H. Margalit,et al.  Sequence signals for generation of antigenic peptides by the proteasome: implications for proteasomal cleavage mechanism. , 2000, Journal of molecular biology.

[4]  Alessandro Sette,et al.  Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method , 2005, BMC Bioinformatics.

[5]  N. Fairweather,et al.  Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. , 1999, Vaccine.

[6]  Wei Xu,et al.  Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine. , 2005, Virology.

[7]  J. Schlom,et al.  A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1 , 2004, Clinical Cancer Research.

[8]  Y. Wan,et al.  How diverse--CD4 effector T cells and their functions. , 2009, Journal of molecular cell biology.

[9]  P. Kloetzel,et al.  Modeling the MHC class I pathway by combining predictions of proteasomal cleavage,TAP transport and MHC class I binding , 2005, Cellular and Molecular Life Sciences CMLS.

[10]  J. McCluskey,et al.  Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. , 2006, Advances in cancer research.

[11]  R. Zinkernagel,et al.  Uncertainties − discrepancies in immunology , 2002, Immunological reviews.

[12]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[13]  H. Grey,et al.  Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Morten Nielsen,et al.  Major histocompatibility complex class I binding predictions as a tool in epitope discovery , 2010, Immunology.

[15]  W. W. Nichols,et al.  Plasmid DNA Vaccines: Investigation of Integration into Host Cellular DNA following Intramuscular Injection in Mice , 2001, Intervirology.

[16]  J. Fagerberg,et al.  T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. , 2003, Blood.

[17]  L. Babiuk,et al.  Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA , 1993, Journal of virology.

[18]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[19]  Freda K. Stevenson,et al.  Critical Components of a DNA Fusion Vaccine Able to Induce Protective Cytotoxic T Cells Against a Single Epitope of a Tumor Antigen1 , 2002, The Journal of Immunology.

[20]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[21]  Alessandro Sette,et al.  The Immune Epitope Database 2.0 , 2009, Nucleic Acids Res..

[22]  J. Palefsky,et al.  Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  James A. Williams,et al.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. , 2009, Biotechnology advances.

[24]  P. Chiarella,et al.  DNA vaccination strategies for anti-tumour effective gene therapy protocols , 2010, Cancer Immunology, Immunotherapy.

[25]  T. Kimman,et al.  Preclinical and Clinical Safety Studies on DNA Vaccines , 2006, Human vaccines.

[26]  C. Andrews,et al.  Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[27]  J. Gribben,et al.  Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies , 2000, Nature Medicine.

[28]  Z. Nagy,et al.  Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning , 1994, The Journal of experimental medicine.

[29]  O. Lund,et al.  NetMHCpan, a method for MHC class I binding prediction beyond humans , 2008, Immunogenetics.

[30]  F. Dorner,et al.  Improvement of the immune response against plasmid DNA encoding OspC of Borrelia by an ER-targeting leader sequence. , 1999, Vaccine.

[31]  R. Levy,et al.  A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. , 1996, Journal of immunology.

[32]  G. Winberg,et al.  Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system , 2003, Cancer Gene Therapy.

[33]  Morten Nielsen,et al.  NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction , 2009, BMC Bioinformatics.

[34]  Margaret A. Liu.  Gene-based vaccines: Recent developments. , 2010, Current opinion in molecular therapeutics.

[35]  Morten Nielsen,et al.  NetCTLpan: pan-specific MHC class I pathway epitope predictions , 2010, Immunogenetics.

[36]  J. Yewdell,et al.  Promiscuous liberation of MHC‐class I‐binding peptides from the C termini of membrane and soluble proteins in the secretory pathway , 1998, European journal of immunology.

[37]  C. Andrews,et al.  Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[39]  J. Schlom,et al.  Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Morten Nielsen,et al.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..

[41]  C. Ottensmeier,et al.  DNA fusion gene vaccines against cancer: from the laboratory to the clinic , 2004, Immunological reviews.

[42]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[43]  Peter Walden,et al.  Exact prediction of a natural T cell epitope , 1991, European journal of immunology.

[44]  Morten Nielsen,et al.  Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan , 2008, PLoS Comput. Biol..

[45]  J. Maguire,et al.  Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. , 2000, Vaccine.

[46]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[47]  L. M. Alvarez-Salas.  Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia. , 2008, Current opinion in molecular therapeutics.

[48]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[49]  L. Silbart,et al.  Modulating gene expression using DNA vaccines with different 3'-UTRs influences antibody titer, seroconversion and cytokine profiles. , 2003, Vaccine.

[50]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[51]  Gabrielle T Belz,et al.  Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity , 2004, Nature Immunology.

[52]  R. Houot,et al.  Vaccines for lymphomas: idiotype vaccines and beyond. , 2009, Blood reviews.

[53]  L. Huston,et al.  Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition. , 2007, International immunology.

[54]  G. Delogu,et al.  DNA Vaccination against Tuberculosis: Expression of a Ubiquitin-Conjugated Tuberculosis Protein Enhances Antimycobacterial Immunity , 2000, Infection and Immunity.

[55]  G. Saglio,et al.  Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. , 2001, Cancer research.

[56]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[57]  V. Fazio,et al.  DNA Vaccines: Developing New Strategies against Cancer , 2010, Journal of biomedicine & biotechnology.

[58]  Mathieu Rouard,et al.  IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. , 2005, Developmental and comparative immunology.

[59]  G. Li Pira,et al.  High Throughput T Epitope Mapping and Vaccine Development , 2010, Journal of biomedicine & biotechnology.

[60]  E. Reinherz,et al.  Prediction of MHC class I binding peptides using profile motifs. , 2002, Human immunology.

[61]  K. P. Murphy,et al.  Janeway's immunobiology , 2007 .

[62]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[63]  O. Lund,et al.  MULTIPRED2: A computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles , 2010, Journal of Immunological Methods.

[64]  Morten Nielsen,et al.  Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods , 2009, Bioinform..

[65]  Bjoern Peters,et al.  Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource. , 2011, Journal of immunological methods.

[66]  Karina Yusim,et al.  Immunoinformatics Comes of Age , 2006, PLoS Comput. Biol..

[67]  T. Hamblin,et al.  DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma , 1998, Nature Medicine.

[68]  Daniel G. Anderson,et al.  Polymeric Materials for Gene Delivery and DNA Vaccination , 2009, Advanced materials.

[69]  J. Rothbard,et al.  Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens , 1985, The Journal of experimental medicine.

[70]  J. Ulmer,et al.  Generation of MHC class I‐restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non‐muscle cells , 1996, Immunology.

[71]  R. Tampé,et al.  The Intracellular Antigen Transport Machinery TAP in Adaptive Immunity and Virus Escape Mechanisms , 2005, Journal of bioenergetics and biomembranes.

[72]  N. Fairweather,et al.  Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli , 1986, Journal of bacteriology.

[73]  R. Hawkins,et al.  Idiotypic DNA Vaccines Against B‐cell Lymphoma , 1995, Immunological reviews.

[74]  S. Ribeiro,et al.  CD4+ T Cell Epitope Discovery and Rational Vaccine Design , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[75]  Morten Nielsen,et al.  State of the art and challenges in sequence based T-cell epitope prediction , 2010, Immunome research.

[76]  V. Fazio,et al.  Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long-Term Tumor-Free Survival in a Mouse Model of Lymphoma , 2010, Journal of biomedicine & biotechnology.

[77]  C. Ottensmeier,et al.  DNA vaccines: precision tools for activating effective immunity against cancer , 2008, Nature Reviews Cancer.

[78]  E. Brown,et al.  Characterization of peptide binding to the murine MHC class I H-2Kk molecule. Sequencing of the bound peptides and direct binding of synthetic peptides to isolated class I molecules. , 1994, Journal of immunology.

[79]  E. Celis,et al.  Peptide epitope identification for tumor-reactive CD4 T cells. , 2008, Current opinion in immunology.

[80]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[81]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[82]  J. Grassi,et al.  Enhancement of antibody responses in DNA vaccination using a vector encoding a universal T-helper cell epitope. , 2004, DNA and cell biology.

[83]  D. Weiner,et al.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. , 1998, The Journal of infectious diseases.

[84]  D. DeLuca,et al.  The immunoinformatics of cancer immunotherapy. , 2007, Tissue antigens.

[85]  R. Levy,et al.  Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. , 1987, Journal of immunology.

[86]  Margaret A. Liu.  DNA vaccines: an historical perspective and view to the future , 2011, Immunological reviews.

[87]  D. Seripa,et al.  Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. , 2008, Biochemical and biophysical research communications.

[88]  A. Hill,et al.  Induction of T Helper Type 1 and 2 Responses to 19-Kilodalton Merozoite Surface Protein 1 in Vaccinated Healthy Volunteers and Adults Naturally Exposed to Malaria , 2002, Infection and Immunity.

[89]  J. Gribben,et al.  Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. , 2001, Blood.

[90]  C. Botev,et al.  Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial , 2000, European Urology.

[91]  M. Blackman,et al.  Vaccine Efficacy of Recombinant Plasmodium falciparumMerozoite Surface Protein 1 in Malaria-Naive, -Exposed, and/or -Rechallenged Aotus vociferans Monkeys , 2000, Infection and Immunity.

[92]  Marie-Paule Lefranc,et al.  IMGT, the international ImMunoGeneTics database. , 1997, Nucleic acids research.

[93]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[94]  J. Schlom,et al.  Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. , 1997, Cancer research.

[95]  S Udenfriend,et al.  Phosphatidylinositol glycan (PI-G) anchored membrane proteins. Amino acid requirements adjacent to the site of cleavage and PI-G attachment in the COOH-terminal signal peptide. , 1992, The Journal of biological chemistry.

[96]  D. Zhu,et al.  DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. , 1997, Journal of immunology.

[97]  F. Rodríguez,et al.  Targeting plasmid‐encoded proteins to the antigen presentation pathways , 2004, Immunological reviews.

[98]  Antonio Lanzavecchia,et al.  The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86 , 1993, European journal of immunology.

[99]  J. Cerottini,et al.  Effects of Epitope Modification on T Cell Receptor–Ligand Binding and Antigen Recognition by Seven H-2Kd–restricted Cytotoxic T Lymphocyte Clones Specific for a Photoreactive Peptide Derivative , 1997, The Journal of experimental medicine.

[100]  Mary S. Wu,et al.  Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. , 2000, Vaccine.

[101]  E. Hersh,et al.  Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma , 2008, Journal of immunotherapy.

[102]  J. Wolchok,et al.  Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  B. Williams,et al.  Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer , 2008, Cancer Immunology, Immunotherapy.

[104]  M. Ramanathan,et al.  Choice of expression vector alters the localization of a human cellular protein. , 2001, DNA and cell biology.

[105]  O. Lund,et al.  An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions , 2005, European journal of immunology.

[106]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[107]  J. Rice,et al.  DNA Fusion Vaccine Designed to Induce Cytotoxic T Cell Responses Against Defined Peptide Motifs: Implications for Cancer Vaccines1 , 2001, The Journal of Immunology.

[108]  F. Stevenson,et al.  Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma. , 2002, Cancer research.

[109]  B. Baker,et al.  Increased Immunogenicity of an Anchor-Modified Tumor-Associated Antigen Is Due to the Enhanced Stability of the Peptide/MHC Complex: Implications for Vaccine Design1 , 2005, The Journal of Immunology.

[110]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.

[111]  Larry R. Smith,et al.  Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine1 , 2001, The Journal of Immunology.

[112]  O. Lund,et al.  NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure , 2010, Immunome research.